Energenesis Biomedical CO.,LTD. (TPE:6657)
Taiwan · Delayed Price · Currency is TWD 29.70
0.00 (0.00%)
Aug 19, 2026, 1:30 PM CST
TPE:6657 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7.64 | 7.67 | 7.75 | 7.16 | 7.35 | 7.49 | |
Revenue Growth | -4.36% | -0.97% | 8.26% | -2.63% | -1.84% | 5.76% |
Cost of Revenue | 2.05 | 1.84 | 2.06 | 1.93 | 2.19 | 2.13 |
Gross Profit | 5.59 | 5.83 | 5.69 | 5.23 | 5.17 | 5.36 |
Selling, General & Admin | 90.65 | 86.68 | 81.01 | 81.94 | 63.14 | 65.69 |
Research & Development | 228.84 | 194.43 | 179.85 | 185.13 | 213.68 | 61.76 |
Operating Expenses | 319.49 | 281.11 | 260.86 | 267.06 | 276.82 | 127.45 |
Operating Income | -313.9 | -275.28 | -255.17 | -261.84 | -271.65 | -122.09 |
Interest Expense | -0.47 | -0.46 | -0.21 | -0.21 | -0.21 | -0.28 |
Interest & Investment Income | 13.72 | 14.87 | 12.51 | 10.44 | 3.93 | 2.41 |
Currency Exchange Gain (Loss) | 1.97 | 1.97 | 11.3 | -8.78 | 2.26 | 0.01 |
Other Non Operating Income (Expenses) | -0.34 | 0.08 | 0.1 | 0.23 | 0.01 | -0.28 |
EBT Excluding Unusual Items | -299.03 | -258.82 | -231.47 | -260.16 | -265.66 | -120.24 |
Gain (Loss) on Sale of Investments | 0.42 | 0.42 | 0.37 | - | - | - |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | - | -0.22 | - | - |
Other Unusual Items | - | - | 0.02 | - | - | - |
Pretax Income | -298.61 | -258.4 | -231.08 | -260.38 | -265.66 | -120.24 |
Net Income | -298.61 | -258.4 | -231.08 | -260.38 | -265.66 | -120.24 |
Net Income to Common | -298.61 | -258.4 | -231.08 | -260.38 | -265.66 | -120.24 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 88 | 88 | 76 | 72 | 67 | 60 |
Shares Outstanding (Diluted) | 88 | 88 | 76 | 72 | 67 | 60 |
Shares Change | 7.35% | 15.89% | 5.97% | 8.08% | 10.96% | 1.67% |
EPS (Basic) | -3.38 | -2.92 | -3.03 | -3.62 | -3.99 | -2.00 |
EPS (Diluted) | -3.38 | -2.92 | -3.03 | -3.62 | -3.99 | -2.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -203.31 | -224.72 | -181.47 | -225.89 | -239.29 | -106.18 |
Free Cash Flow Per Share | -2.30 | -2.54 | -2.38 | -3.14 | -3.59 | -1.77 |
Gross Margin | 73.14% | 76.00% | 73.43% | 73.02% | 70.26% | 71.56% |
Operating Margin | -4108.60% | -3587.11% | -3292.93% | -3657.96% | -3695.47% | -1630.26% |
Profit Margin | -3908.52% | -3367.24% | -2982.06% | -3637.64% | -3613.98% | -1605.50% |
Free Cash Flow Margin | -2661.10% | -2928.30% | -2341.79% | -3155.81% | -3255.16% | -1417.84% |
EBITDA | -302.71 | -258.92 | -238.69 | -244.58 | -253.78 | -105.63 |
D&A For EBITDA | 11.19 | 16.35 | 16.48 | 17.26 | 17.88 | 16.46 |
EBIT | -313.9 | -275.28 | -255.17 | -261.84 | -271.65 | -122.09 |